- Home
- SENEA vs EYPT Comparison
SENEA vs EYPT Comparison
Compare SENEA & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEA | EYPT |
|---|---|---|
| Founded | 1949 | 1987 |
| Country | United States | United States |
| Employees | 6895 | N/A |
| Industry | Packaged Foods | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 949.4M | 1.1B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | SENEA | EYPT |
|---|---|---|
| Price | $159.45 | $13.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $31.80 |
| AVG Volume (30 Days) | 80.3K | ★ 1.1M |
| Earning Date | 02-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,031.72 |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $81.00 | $3.91 |
| 52 Week High | $165.26 | $19.11 |
Technical Indicators
Market Signals| Indicator | SENEA | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 77.72 | 46.16 |
| Support Level | $101.00 | $12.47 |
| Resistance Level | N/A | $14.54 |
| Average True Range (ATR) | 5.98 | 0.72 |
| MACD | 0.77 | -0.01 |
| Stochastic Oscillator | 83.97 | 69.30 |
Price Performance
Historical ComparisonAbout SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.